CXCL-12 receptor 4 (CXCR4) inhibitors can be applied to recruit T cells to accumulate in cancer cells as well as cooperate with α-PD-L1 to significantly reduce the number of tumor cells [56]. This evidence concerns the gene CXCR4 and cancer.